Pharma giant Sanofi and partner AstraZeneca have bolstered the manufacturing and shipping capacity of Beyfortus to ensure broad availability ahead of the 2025–2026 respiratory syncytial virus (RSV) season.
The companies are doing this to ensure that healthcare providers can successfully immunise individuals ahead of the period, which generally begins in November and ends in March.
This follows the soar in demand for the monoclonal antibody vaccine, which is the only RSV jab on the market that offers protection for all infants, according to Sanofi.
Since the launch of Beyfortus in 2023, Sanofi and AstraZeneca have tripled its production capacity, while doubling the number of manufacturing sites available for its production.
Current supply of Beyfortus for the upcoming season already matches the total doses distributed last year, though the company plans to produce more to keep up with demand.
This year, shipments of the vaccines made to the EU feature a label extending the duration of protection through six months — meaning Beyfortus offers season-long protection for all infants immunised before RSV season begins.
With an extended half-life of 71 days, Beyfortus is the longest-acting monoclonal antibody that protects infants from RSV lower respiratory tract disease, and the only immunisation suitable for all infants born before or during the RSV season; whether they were born pre- or at term.
The vaccine is also available for children up to 2 years of age who remain vulnerable to RSV disease the following year
“Our third year of providing RSV protection marks a transformative era in infant health," noted Thomas Triomphe, Executive VP of Vaccines at Sanofi.
"Backed by more than 40 real-world studies involving 250,000 immunised infants, Beyfortus has consistently proven itself as an effective RSV immunisation."
"To meet growing demand since launch, we have meticulously primed our global distribution network to ensure Beyfortus will continue to deliver significant public health impact and offer high, sustained efficacy for infants regardless of underlying health conditions or the timing of when they are born,” he concluded.